Skin disease in dermatomyositis

Current Opinion in Rheumatology

Volumn 24, Issue 6, 2012, Pages 597-601

  Zaba, Lisa C ^a   Fiorentino, David F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyopathic; cutaneous; dermatomyositis; interferon; melanoma differentiation associated gene 5 IFIH1

Indexed keywords

ABATACEPT; ALPHA INTERFERON; ANGIOPOIETIN 2; AZATHIOPRINE; BETA INTERFERON; CHONDROITIN 4 SULFATE; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SODIUM THIOSULFATE; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

CALCINOSIS; CELLULAR IMMUNITY; CLINICAL FEATURE; DERMATITIS; DERMATOMYOSITIS; DRUG ERUPTION; GENE EXPRESSION; HUMAN; MUSCLE TISSUE; MYOSITIS; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; SKIN CALCIFICATION; SKIN DISEASE; SKIN EXAMINATION; TREATMENT OUTCOME;

AUTOIMMUNITY; CALCINOSIS; DERMATOMYOSITIS; HUMANS; PATIENT SELECTION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN DISEASES;

EID: 84866975700     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283585748     Document Type: Review

References (38)

1. Goreshi R, Chock M, Foering K, et al. Quality of life in dermatomyositis. J Am Acad Dermatol 2011; 65:1107-1116.
2. Shrestha S, Wershil B, Sarwark JF, et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 2010; 62:2813-2822.
3. GrassiM, Capello F, Bertolino L, et al. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol 2009; 34:910-914.
4. Torchia D, Caproni M, Volpi W, et al. The Fas/Fas ligand system, rather than granzyme B, may represent the main mediator of epidermal apoptosis in dermatomyositis. Clin Exp Dermatol 2010; 35:669-670.
5. Antiga E, Kretz CC, Klembt R, et al. Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun 2010; 35:342-350.
6. Magro CM, Segal JP, Neil Crowson A, Chadwick P. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 2010; 37:659-671.
7. Wong D, Kea B, Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PloS one 2012; 7:e29161.
8. Nabatian AS, Bashir MM, Wysocka M, et al. Tumor necrosis factor alpha release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. Arthritis Res Ther 2012; 14:R1.
9. Zahn S, Rehkamper C, Kummerer BM, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Invest Dermatol 2011; 131:133-140.
10. Kim JS, Werth VP. Identification of specific chondroitin sulfate species in cutaneous autoimmune disease. J Histochem Cytochem 2011; 59:780-790.
11. Ogata A, Endo M, Aoi J, et al. The role of angiopoietin-like protein 2 in pathogenesis of dermatomyositis. Biochem Biophys Res Commun 2012; 418:494-499.
12. Kim JS, Bashir MM, Werth VP. Gottron's papules exhibit dermal accumulation of CD44 Variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. J Invest Dermatol 2012; 132:1825-1832.
13. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010; 146:26-30.
14. Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2011; 21:178-183.
15. Lofgren S, Mann J, White C, Krol A. Juvenile dermatomyositis presenting as an acquired inflammatory Blaschko-linear dermatosis. J Am Acad Dermatol 2011; 65:e134-e135.
16. Takahashi Y, Murota H, Tarutani M, et al. A case of juvenile dermatomyositis manifesting inflammatory epidermal nevus-like skin lesions: unrecognized cutaneous manifestation of blaschkitis? Allergol Int 2010; 59:425-428.
17. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25-34.
18. Quinter SD, Chiu YE, Lyon VB, et al. Inverse Gottron's Papules: an unusual cutaneous manifestation of juvenile dermatomyositis. Pediatr Dermatol 2011. [Epub ahead of print]
19. Ikeda N, Takahashi K, Yamaguchi Y, et al. Analysis of dermatomyositisspecific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 2011; 38:973-979.
20. Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/ dermatomyositis. Arthritis Res Ther 2012; 14:R97.
21. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60:1807-1814.
22. Morganroth PA, Kreider ME, Okawa J, et al. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 2010; 146:729-738.
23. Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 2011; 38:1636-1643.
24. Goreshi R, Okawa J, Rose M, et al. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol 2012; 132:1117-1124.
25. Mugii N, Hasegawa M, Matsushita T, et al. Association between nail-fold capillary findings and disease activity in dermatomyositis. Rheumatology 2011; 50:1091-1098.
26. Ostrowski RA, Sullivan CL, Seshadri R, et al. Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. Arthritis Rheum 2010; 62:1533-1538.
27. Schmeling H, Stephens S, Goia C, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology 2011; 50:885-893.
28. Hornung T, Ko A, Tuting T, et al. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol 2012; 37:139-142.
29. Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res 2010; 62:1446-1451.
30. Dagher R, Desjonqueres M, Duquesne A, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int 2012; 32:711-716.
31. Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol 2012; 30:397-401.
32. Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry. J Rheumatol 2011; 38:1436-1440.
33. Amato A, Tawil R, Kissel J, et al. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70:427-436.
34. Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatology 2012; 148:455-462.
35. Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 2010; 28:135-140.
36. Mori H, Okada Y, Yamaoka K, et al. Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy. J Bone Miner Metab 2012; 30:114-118.
37. Miyamae T, Mori M, Inamo Y, et al. Multicenter analysis of calcinosis in children with juvenile dermatomyositis. Ryumachi 2003; 43:538-543. (Pubitemid 36958545)
38. Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012; 160:520-522.